Transglutaminase for inhibiting angiogenesis
US7704943B2 · kind B2 · utility
28Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 8, 2001 |
| Grant date | Apr 27, 2010 |
| Priority date | — |
| Expiry date | Dec 28, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to use of a transglutaminase in the preparation of a medicament for inhibiting angiogenesis. Preferably, the transglutaminase is a human tissue transglutaminase. Advantageously, the medicament is for treating cancer, rheumatoid arthritis, retinopathy and/or psoriasis. Additionally, the invention relates to compositions comprising a transglutaminase in an amount sufficient to inhibit angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.